---
title: "Chunli Medical's net profit attributable to the parent company in 2025 is approximately 272 million yuan, a year-on-year increase of 117.72%"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/277191188.md"
description: "Chunli Medical announced its performance preliminary report for the year 2025, with total operating revenue of approximately 1.044 billion yuan, a year-on-year increase of 29.52%; net profit attributable to the parent company's owners of approximately 272 million yuan, a year-on-year increase of 117.72%; basic earnings per share of 0.71 yuan. The growth in performance is mainly attributed to the promotion of national centralized procurement of orthopedic consumables and the steady development of international business, which has driven the overall revenue and profitability of the company"
datetime: "2026-02-27T11:43:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277191188.md)
  - [en](https://longbridge.com/en/news/277191188.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277191188.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/277191188.md) | [繁體中文](https://longbridge.com/zh-HK/news/277191188.md)


# Chunli Medical's net profit attributable to the parent company in 2025 is approximately 272 million yuan, a year-on-year increase of 117.72%

According to the Zhitong Finance APP, Chunli Medical (01858) announced its performance report for the fiscal year 2025, with total operating revenue of approximately 1.044 billion yuan, a year-on-year increase of 29.52%; net profit attributable to the parent company's owners of approximately 272 million yuan, a year-on-year increase of 117.72%; and basic earnings per share of 0.71 yuan.

During the reporting period, the company's product procurement growth potential continued to be released after implementation, international business steadily advanced, and internal and external collaboration drove steady revenue growth; at the same time, the company continuously optimized its management and resource allocation, further enhancing operational efficiency and profitability, collectively driving good growth in performance.

The announcement stated that the main reason for the performance growth was: with the normalization of national procurement for orthopedic consumables, the company relied on a comprehensive channel coverage network and a rich product system, leading to a steady increase in product sales, continuous expansion of domestic business scale and market share, and steady improvement in profitability. The company continues to promote its internationalization strategy, relying on product technology and quality standards that reach international advanced levels, achieving continuous expansion and breakthroughs in the international market, with overseas revenue steadily increasing, providing important support for the overall performance growth of the company.

At the same time, the company focuses on refined operational management and optimizes operational efficiency; through large-scale production, it further strengthens scale effects, significantly improving overall operational efficiency and profitability

### 相关股票

- [Chunli Medical (688236.CN)](https://longbridge.com/zh-CN/quote/688236.CN.md)

## 相关资讯与研究

- [Blanche: I never heard Trump say Bondi exit ‘had anything to do with the Epstein files’](https://longbridge.com/zh-CN/news/281637342.md)
- [Trump to sign order to pay tens of thousands of DHS employees](https://longbridge.com/zh-CN/news/281556389.md)
- [North Western Railway to run special trains until July 15 amid summer rush](https://longbridge.com/zh-CN/news/281603955.md)
- [11:33 ETFitness, Health and Wellness Experts Team Up to 'Get Fit for No Kid Hungry' with New On-Demand Initiative](https://longbridge.com/zh-CN/news/281213207.md)
- [Assessing Zealand Pharma (CPSE:ZEAL) Valuation After New AI-Focused Cambridge Research Hub Announcement](https://longbridge.com/zh-CN/news/281697025.md)